A provider-focused briefing on the Bupivacaine shortage in 2026. Coverage of timeline, clinical alternatives, sourcing strategies, and patient tools.
Bupivacaine Hydrochloride Injection has been on the FDA and ASHP drug shortage lists since June 2023. Nearly three years later, supply remains inconsistent across multiple formulations and concentrations. For anesthesiologists, surgeons, pain management specialists, and other proceduralists, the shortage has forced ongoing adaptations in clinical practice, procurement, and patient communication.
This briefing covers the current state of the shortage, clinical implications, alternative protocols, and tools to help your patients maintain access.
Understanding the trajectory of this shortage provides context for current supply conditions:
The prolonged shortage has several practical consequences for providers:
Many hospitals and surgical centers have implemented Bupivacaine conservation protocols, including:
The clinical alternatives for providers include:
For a patient-facing resource you can share, see: Alternatives to Bupivacaine.
As of early 2026, availability varies significantly by manufacturer, concentration, and whether the formulation is preservative-free:
FDA-authorized imported Bupivacaine (typically in ampule form rather than vials) may be available through major distributors. Providers should verify that imported products are on the FDA's temporary importation authorization list.
Bupivacaine is a relatively inexpensive generic — a 50 mL vial of 0.5% generic Bupivacaine typically costs $9 to $40. However, shortage conditions have introduced pricing variability:
For patients concerned about costs, you can direct them to: How to Save Money on Bupivacaine.
Medfinder for Providers helps you direct patients to pharmacies and facilities that have Bupivacaine in stock. During shortage conditions, this can reduce canceled procedures and patient frustration.
The ASHP maintains detailed shortage entries for Bupivacaine with manufacturer-specific notes, estimated resupply dates, and therapeutic alternatives. This should be part of your regular shortage monitoring workflow.
The FDA's database includes information on temporary importation authorizations, which is critical for procurement teams evaluating imported supply.
The sterile injectable drug shortage crisis extends beyond Bupivacaine — it's a systemic issue affecting dozens of critical medications. Industry groups, the FDA, and Congress have taken steps to address root causes (manufacturing quality incentives, supply chain transparency requirements), but meaningful resolution will take years.
In the meantime, providers who stay informed, maintain flexible protocols, and leverage tools like Medfinder will be best positioned to maintain patient care continuity.
The Bupivacaine shortage is a stress test for anesthesia and surgical practice. While alternatives exist and imported supply helps bridge gaps, the situation requires ongoing vigilance. Keep your teams informed, your protocols updated, and your patients supported with clear communication about what the shortage means for their care.
Related resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
